Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
China
· Delayed Price · Currency is CNY 48.64
-0.33 (-0.67%)
At close: Mar 9, 2026
Shanghai OPM Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 354.91 | 296.78 | 242.69 | 294.27 | 212.68 | Upgrade
|
| Other Revenue | - | 0.47 | 0.43 | 0.1 | - | Upgrade
|
| Revenue | 354.91 | 297.24 | 243.12 | 294.37 | 212.68 | Upgrade
|
| Revenue Growth (YoY) | 19.40% | 22.26% | -17.41% | 38.41% | 70.19% | Upgrade
|
| Cost of Revenue | - | 142.34 | 101.53 | 107.25 | 86 | Upgrade
|
| Gross Profit | 354.91 | 154.9 | 141.59 | 187.12 | 126.69 | Upgrade
|
| Selling, General & Admin | - | 105.94 | 74.47 | 60 | 50.96 | Upgrade
|
| Research & Development | - | 33.37 | 41.91 | 32.19 | 19.03 | Upgrade
|
| Other Operating Expenses | 305.31 | 2.21 | -0.23 | 1.17 | 0.78 | Upgrade
|
| Operating Expenses | 305.31 | 148.44 | 122.57 | 98.11 | 71.09 | Upgrade
|
| Operating Income | 49.6 | 6.46 | 19.02 | 89 | 55.6 | Upgrade
|
| Interest Expense | - | -3.12 | -3.23 | -4.98 | -4.79 | Upgrade
|
| Interest & Investment Income | - | 31.14 | 36.3 | 17.98 | 9.07 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 2.4 | 0.87 | 2.24 | -0.24 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.23 | -0.05 | -0.09 | -0.14 | -0.07 | Upgrade
|
| EBT Excluding Unusual Items | 49.37 | 36.84 | 52.89 | 104.09 | 59.57 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 4.63 | 1.53 | 1.67 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.09 | -0.02 | 0.29 | -0.02 | Upgrade
|
| Asset Writedown | - | -7.51 | - | - | - | Upgrade
|
| Other Unusual Items | - | 2.38 | 7.26 | 13.38 | 8.61 | Upgrade
|
| Pretax Income | 49.37 | 36.43 | 61.67 | 119.43 | 68.15 | Upgrade
|
| Income Tax Expense | 7.67 | 16.19 | 8.41 | 14.06 | 7.76 | Upgrade
|
| Earnings From Continuing Operations | 41.7 | 20.24 | 53.26 | 105.37 | 60.39 | Upgrade
|
| Minority Interest in Earnings | - | 0.82 | 0.78 | - | - | Upgrade
|
| Net Income | 41.7 | 21.05 | 54.04 | 105.37 | 60.39 | Upgrade
|
| Net Income to Common | 41.7 | 21.05 | 54.04 | 105.37 | 60.39 | Upgrade
|
| Net Income Growth | 98.07% | -61.04% | -48.72% | 74.47% | 416.87% | Upgrade
|
| Shares Outstanding (Basic) | 113 | 111 | 115 | 101 | 86 | Upgrade
|
| Shares Outstanding (Diluted) | 113 | 117 | 115 | 101 | 86 | Upgrade
|
| Shares Change (YoY) | -3.64% | 1.72% | 13.48% | 17.43% | 0.20% | Upgrade
|
| EPS (Basic) | 0.37 | 0.19 | 0.47 | 1.04 | 0.70 | Upgrade
|
| EPS (Diluted) | 0.37 | 0.18 | 0.47 | 1.04 | 0.70 | Upgrade
|
| EPS Growth | 105.56% | -61.70% | -54.81% | 48.57% | 415.84% | Upgrade
|
| Free Cash Flow | - | -51.61 | -19.59 | -35.34 | 8.64 | Upgrade
|
| Free Cash Flow Per Share | - | -0.44 | -0.17 | -0.35 | 0.10 | Upgrade
|
| Dividend Per Share | - | 0.420 | 0.440 | 0.429 | - | Upgrade
|
| Dividend Growth | - | -4.47% | 2.66% | - | - | Upgrade
|
| Gross Margin | 100.00% | 52.11% | 58.24% | 63.57% | 59.56% | Upgrade
|
| Operating Margin | 13.98% | 2.17% | 7.82% | 30.23% | 26.14% | Upgrade
|
| Profit Margin | 11.75% | 7.08% | 22.23% | 35.80% | 28.40% | Upgrade
|
| Free Cash Flow Margin | - | -17.36% | -8.06% | -12.01% | 4.06% | Upgrade
|
| EBITDA | 85.36 | 42.22 | 47.04 | 113.28 | 74.34 | Upgrade
|
| EBITDA Margin | 24.05% | 14.21% | 19.35% | 38.48% | 34.96% | Upgrade
|
| D&A For EBITDA | 35.76 | 35.76 | 28.02 | 24.28 | 18.74 | Upgrade
|
| EBIT | 49.6 | 6.46 | 19.02 | 89 | 55.6 | Upgrade
|
| EBIT Margin | 13.98% | 2.17% | 7.82% | 30.23% | 26.14% | Upgrade
|
| Effective Tax Rate | 15.54% | 44.45% | 13.63% | 11.78% | 11.39% | Upgrade
|
| Revenue as Reported | - | 297.24 | 243.12 | 294.37 | 212.68 | Upgrade
|
| Advertising Expenses | - | 2.08 | 2.29 | 1.34 | 0.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.